Serial CEA serum measurements were recommended in a 2014 update of the European group on tumor marker guidelines for postoperative surveillance of UICC stage II and III patients considered for surgical resection or systemic therapy in case of distant metastasis and for monitoring response to treatment in advanced disease [56]. This evidence concerns the gene CEACAM5 and neoplasm.